Chardan Capital Analysts Lower Earnings Estimates for Femasys Inc. (NASDAQ:FEMY)

Femasys Inc. (NASDAQ:FEMY) – Chardan Capital cut their FY2024 earnings per share (EPS) estimates for Femasys in a research note issued to investors on Wednesday, August 14th. Chardan Capital analyst K. Nakae now forecasts that the company will post earnings of ($0.79) per share for the year, down from their previous estimate of ($0.75). Chardan Capital has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Femasys’ current full-year earnings is ($0.72) per share. Chardan Capital also issued estimates for Femasys’ FY2025 earnings at ($0.56) EPS.

Femasys (NASDAQ:FEMY) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.03). Femasys had a negative net margin of 1,420.59% and a negative return on equity of 104.06%. The business had revenue of $0.22 million during the quarter, compared to analyst estimates of $0.50 million.

Separately, HC Wainwright lowered their target price on Femasys from $13.00 to $12.00 and set a “buy” rating on the stock in a research report on Friday, August 9th.

Femasys Price Performance

Shares of NASDAQ:FEMY opened at $1.09 on Monday. The company has a quick ratio of 8.02, a current ratio of 8.43 and a debt-to-equity ratio of 0.29. Femasys has a twelve month low of $0.25 and a twelve month high of $4.75. The stock’s 50 day moving average is $1.09 and its 200-day moving average is $1.31. The firm has a market capitalization of $24.22 million, a price-to-earnings ratio of -1.30 and a beta of -2.81.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Femasys stock. Clear Creek Financial Management LLC boosted its stake in Femasys Inc. (NASDAQ:FEMY) by 30.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 309,274 shares of the company’s stock after purchasing an additional 72,505 shares during the quarter. Clear Creek Financial Management LLC owned approximately 1.40% of Femasys worth $479,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 65.27% of the company’s stock.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.